Amanda Massmann

Dr. Amanda Massmann

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2023 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
SCSavannah Collett
Savannah Collett
AMAmanda Massmann
Amanda Massmann
NPNatasha J. Petry
Natasha J. Petry
JHJoel Van Heukelom
Joel Van Heukelom
ASApril Schultz
April Schultz
JBJordan Baye
Jordan Baye
Metoprolol is a medication commonly utilized in select patients to achieve a reduction in heart rate, systolic blood pressure, or other indications. A majority of metoprolol metabolism occurs via CYP2D6. Decreased expression of the CYP2D6 enzyme increases the concentration of metoprolol. Current pharmacogenomics guidelines by the Dutch Pharmacogenomics Working Group recommend slower titrations and dose decreases to minimize adverse effects from poor metabolizers or normal metabolizers taking concomitant medications that are strong inhibitors of CYP2D6 (phenoconverters). This study aimed to evaluate adverse effects such as bradycardia, hypotension, and syncope in patients who are expected to have absent CYP2D6 enzyme activity due to drug–drug or drug–gene interactions. The secondary aims of this study were to evaluate heart rate measurements for the included participants. Retrospective data were collected for individuals with CYP2D6 genotyping results obtained for clinical purposes. Three categories (CYP2D6 normal metabolizers, poor metabolizers, and phenoconverters) were assigned. A total of 325 participants were included. There was no statistically significant difference found in the primary composite outcome between the three metabolizer groups (p = 0.054). However, a statistically significant difference was identified in the incidences of bradycardia between the poor metabolizers and the normal metabolizers or phenoconverters (p < 0.0001). The average heart rates were 2.8 beats per minute (bpm) and 2.6 bpm lower for the poor metabolizer and phenoconverter groups, respectively, compared to the normal metabolizers (p < 0.0001 for both comparisons). This study further supports the role of genetic testing in precision medicine to help individualize patient care as CYP2D6 poor metabolizers taking metoprolol were found to have an increase in bradycardia. Additional research is needed to clarify the dose relationship in this drug–gene interaction.

17 July 2023 in Pharmacogenomics
Verified
Journal Article
Closed access
CPCharlene L Preys
Charlene L Preys
CZCarrie L Blout Zawatsky
Carrie L Blout Zawatsky
AMAmanda Massmann
Amanda Massmann
JHJoel Van Heukelom
Joel Van Heukelom
RGRobert C Green
Robert C Green
KCKurt Christensen
Kurt Christensen
Aim: To understand how attitudes toward pharmacogenomic (PGx) testing among healthcare providers varies by specialty. Methods: Providers reported comfort ordering PGx testing and its perceived util...

29 February 2024 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
AMAmanda Massmann
Amanda Massmann
KCKurt Christensen
Kurt Christensen
JHJoel Van Heukelom
Joel Van Heukelom
ASApril Schultz
April Schultz
MSMuhammad Hamza Saad Shaukat
Muhammad Hamza Saad Shaukat
TSTomasz P. Stys
Tomasz P. Stys

8 May 2023 in American Journal of Health-System Pharmacy
Verified
Journal Article
Closed access
PDF file
AMAmanda Massmann
Amanda Massmann
NPNatasha J. Petry
Natasha J. Petry
In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. To compare rates of prescriber acceptance of interruptive and noninterruptive clinical decision support (CDS) alerts regarding potential diminished therapeutic effectiveness and safety risks associated with proton pump inhibitor (PPI) use in carriers of gene variants affecting cytochrome P450 (CYP) isozyme 2C19 metabolism. A retrospective study was conducted at a large rural health system to examine different approaches to improving CDS alert acceptance while minimizing alert fatigue. Manual reviews were conducted to identify alerts regarding CYP2C19 metabolizer status displayed at the time of PPI ordering over 30-day periods before and after the transition from interruptive to noninterruptive CDS alert functionality. A chi-square test was conducted to analyze prescriber acceptance CDS recommendations by alert modality and type of treatment modification. Overall, interruptive alerts had an acceptance rate of 18.6% (64/344), compared to 8.4% acceptance (30/357 alerts) for noninterruptive alerts (P ≤ 0.0001). Analysis of acceptance criteria revealed the noninterruptive alert cohort had higher acceptance, as determined by documented medication dose adjustments, than the interruptive alert cohort (53.3% [16/30] and 4.7% [3/64], respectively). The difference in acceptance rates by CDS modality and treatment modification was statistically significant (P ≤ 0.00001). The predominant indication for PPI use was gastroesophageal reflux disease (GERD) in both cohorts. Interruptive alerts that actively influenced workflow had higher acceptance rates than noninterruptive alerts that served an informational purpose without a direct disruption of workflow. The study results suggest the utilization of noninterruptive alerts may be a beneficial tool for prompting clinicians to alter dosing regimens rather than transition to an alternative agent.

1 July 2022 in Pharmacogenomics
Verified
Journal Article
Closed access
NPNatasha J. Petry
Natasha J. Petry
JBJordan Baye
Jordan Baye
SFSamantha Frear
Samantha Frear
KJKristen Jacobsen
Kristen Jacobsen
AMAmanda Massmann
Amanda Massmann
KCKurt Christensen
Kurt Christensen
Background: Statins are among the most commonly prescribed medications, and improve patient outcomes by lowering cholesterol levels, but also have side effects. Variations in statin response can be...

26 April 2023 in Pharmacogenomics
Verified
Journal Article
Closed access
JHJoel Van Heukelom
Joel Van Heukelom
KJKristen Jacobsen
Kristen Jacobsen
NPNatasha J Petry
Natasha J Petry
ASApril Schultz
April Schultz
JBJordan Baye
Jordan Baye
AMAmanda Massmann
Amanda Massmann
Background: Returning pharmacogenomic (PGx) results to patients is complex and challenging. Patients prefer provider education; however, a gap in provider comfort in PGx results has been documented...